MarketPulse

Eylea

2 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Regeneron Stock Rally Masks Reality: Respectable Returns, Not Millionaire-Maker Gains

Regeneron's 35% recovery masks limited multimillionaire potential at $79B valuation, positioning shares for S&P-matching returns rather than exceptional gains.
REGNbiotechclinical trials
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Regeneron's Pipeline Depth and Dupixent Dominance Set Stage for Decade of Growth

Regeneron's Dupixent dominance and deep pipeline across weight management, oncology, and rare diseases position the company for sustained growth through the mid-2030s.
REGNbiotechpatent cliff